Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia   Pronzato Paolo   Del Mastro Lucia  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite

A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer

By Yardley Denise   Burris Howard   Peacock Nancy   Raefsky Eric   Melnik Marianne   Inhorn Roger   Shipley Dianna   Hainsworth John  

Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. : 471-475

Springer Publishing Company

Access to resources Recommend Favorite

Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data

By Eiermann W.  

Annals of Oncology, Vol. 12, Iss. 12, 2001-12 ,pp. : 57-62

Springer Publishing Company

Access to resources Recommend Favorite

HER2-positive Breast Cancer Brain Metastases: Multiple Responses to Systemic Chemotherapy and Trastuzumab—a Case Report

By Church D.   Bahl A.   Jones A.   Price C.  

Journal of Neuro-Oncology, Vol. 79, Iss. 3, 2006-09 ,pp. : 289-292

Springer Publishing Company

Access to resources Recommend Favorite

Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy

By Kim Ji-Won   Kim Jee   Im Seock-Ah   Lee Kyung-Hun   Kim Jin-Soo   Kim Tae-Yong   Han Sae-Won   Jeon Yoon   Oh Do-Youn   Kim Tae-You   Park In  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 1023-1029

Springer Publishing Company

Access to resources Recommend Favorite